Recently, Shenzhen Junsheng Tai Biotechnology Co.
, Ltd.
announced the completion of a series C + financing
of 107 million US dollars.
It is reported that Junsheng Tai is a global integrated clinical-stage biotechnology company
.
Since its establishment in 2011, based on source innovation, Junsheng Tai has always aimed at the comprehensive clinical benefits and overall health improvement of patients, based on traditional natural medicines with clear pharmacological activity, integrated modern drug design and development concepts, and has built a rich pipeline of multi-target original innovative drugs, and embarked on its own path
of modern innovation and development of traditional Chinese medicine.
For example, its core variety, HTD1801, is a new molecular entity synthesized by berberine and ursodeoxycholic acid, targeting four indication markets, namely type 2 diabetes mellitus (T2DM), nonalcoholic steatohepatitis (NASH), hypertriglyceridemia (SHTG) and cholestatic liver disease
.
R&D strength is the core competitiveness of innovative drug companies, and according to the announcement, the funds raised in this round will be used to promote the global development, commercialization and business development
of a number of clinical pipelines in Junshengtai.
In fact, in recent years, under the strategic plan of the state to vigorously promote the "modernization of traditional Chinese medicine", many pharmaceutical companies are developing original Chinese medicine new drugs
by inheriting the essence, keeping the right innovation, based on traditional natural medicines with clear pharmacological activity, complying with international drug development standards, and integrating modern drug design and development concepts.
For example, Tasly is one of the landmark enterprises of the internationalization of modern Chinese medicine, with more than 20 scientific research centers around the world, and has also been approved by the Ministry of Science and Technology of the People's Republic of China to establish the "State Key Laboratory of Key Technologies of Innovative Chinese Medicine"
.
Over the years, Tasly has adhered to the strategy of "large varieties" and "internationalization" of traditional Chinese medicine, built key technologies for innovation and internationalization of traditional Chinese medicine and carried out synchronous research and development at home and abroad, focusing on the fields of cardiovascular and cerebrovascular, digestive metabolism, rheumatology and immunology, gynecology and pediatrics, and is committed to providing drugs
that are urgently needed clinically and even fill the gap in the clinical market 。 Up to now, it has obtained a total of 19 domestic registration approvals, 54 clinical licenses, 2 EU plant drug approvals, and 450 registration approvals for "Belt and Road" countries and regions; Undertake and participate in 117 national 863, 973, key research and development plans, national science and technology major projects
, etc.
In addition, in recent years, Yiling Pharmaceutical is also making full use of the methods and means of modern science and technology to continuously increase investment in scientific research and leapfrog development of innovative Chinese medicine drugs on the basis of inheriting and carrying forward the advantages and characteristics of traditional Chinese medicine
.
According to public information, from 2016 to 2021, the R&D investment of Yiling Pharmaceutical was 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan and 838 million yuan, ranking the leading level
in the same industry.
In 2022, Yiling Pharmaceutical will continue to increase R&D investment and lead development with innovation, and its R&D expenses in the first three quarters will reach 552 million yuan
.
At present, it has developed a series of patented traditional Chinese medicines
with independent intellectual property rights around six major diseases of cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurological and urinary diseases, and large market dosage.
Among them, there are 13 patented new drugs, of which 8 are listed in the national medical insurance catalogue and 5 are listed in the national essential drug list, which provides an important driving force
for the company's performance growth.
In general, the clinical value of traditional Chinese medicine has been obvious
to all.
The industry expects that in the future, under the background of the continuous acceleration of the modernization of traditional Chinese medicine, with its core scientific research strength, efficient industrial chain management and brand advantages, many traditional Chinese medicine enterprises will usher in greater performance growth space
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
